Guardant Health wins FDA nod for Guardant360 CDx as breast cancer companion diagnostic for AstraZeneca camizestrant

PUBT · 1d ago
Guardant Health wins FDA nod for Guardant360 CDx as breast cancer companion diagnostic for AstraZeneca camizestrant
  • FDA cleared Guardant Health’s Guardant360 CDx as a companion diagnostic for AstraZeneca’s ETCAMAH (camizestrant) in advanced breast cancer.
  • Test identifies HR-positive, HER2-negative patients with ESR1 mutations before radiographic progression for camizestrant treatment.
  • Approval supported by SERENA-6 data showing a 56% lower risk of progression or death with an early switch to camizestrant.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260904644799) on September 04, 2026, and is solely responsible for the information contained therein.